By Brian Marckx, CFA
READ THE FULL CASM RESEARCH REPORT
Q4 2019 Preannouncement, Initial 2019 Guidance, OEM Cable Launch Expected Mid-2019
Post-market close yesterday, CAS Medical (CASM) released preliminary Q4 revenue and monitor placement numbers and provided initial (general) guidance for how they think 2019 may shape up. Note, however, that this current 2019 guidance, of low double-digit FORE-SIGHT sales growth (inline with our prior and current estimates), does not include any potential contribution from their OEM smart cable product – which management now thinks will launch around mid-year. Company guidance will be updated following the launch.
As it relates to the Q4, revenue of approximately $5.8M represents growth of 13% yoy and about 8% from Q3’18. It also represents a new record high. FORE-SIGHT sensors, up 20% yoy, remain the catalyst that is driving the top-line. Sensors revenue jumped 10% from the prior quarter – which had been the previous record high. Sensors sales benefitted from a particularly strong showing OUS – up 50% yoy and approximately +46% qoq. But, U.S. sales, also experienced positive traction – up 16% yoy and about 5% better sequentially.
Particularly encouraging, in our opinion, is that not only is sensors revenue growing (the lack of which over the recent past had been a concern of ours), but utilization per U.S. installed monitor (based on our rough calculation) appears to be largely stable. As intuitively, we would expect some erosion in per-monitor utilization with aggregate growth of the installed base, static utilization is quite encouraging. This has been the case for the last six consecutive quarters.
Q4 total revenue is about 6% better than what we had been expecting – we have since updated our FY2018 numbers. This update, along with some minor other tweaks to our Q4 income statement, result in a slight improvement in projected full-year net loss, which has moved from $7.5M (previously) to $7.4M (currently). Full-year 2018 estimated EPS is unchanged at ($0.27). We are maintaining our $4.50/share price target.
Management’s initial 2019 guidance is largely inline with our prior and current thinking. They expect low double-digit percentage FORE-SIGHT sales from low-teens growth in the U.S. and high single-digit growth overseas. U.S. FORE-SIGHT growth is anticipated to be driven by mid-teens growth of sensors. As noted, this guidance has yet to include any assumed contribution from their OEM smart cable.
As a reminder, 510(k) clearance of this product was obtained in May 2018. It is expected to provide all of the same FORE-SIGHT functionality but without the need for CASM’s monitor (instead, a cable will interface between third-party monitors and the FORE-SIGHT sensors). CASM already has a partnership (with more possibly to come) with one third-party monitor manufacturer. Per yesterday’s press release, CASM shipped an initial batch of the product to this (yet-to-be named) partner in late-December.
Commercialization is predicated on FDA 510(k) clearance for the combination product. Per management’s comments on the Q3 call in November, that regulatory filing is expected by Q1 2019. If all goes well, the product will be cleared (at which time we should also know the identity of their partner) and launched by around mid-year. Potential benefits include efficient distribution channels and immediate expansion of their Rolodex and sales reach.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.
By Brian Marckx, CFA